

indemnity for the annual vacation equal to 6.36 % and an indemnity for general holidays equal to 4 %.

6.03.1. Employer's obligation: The employer includes those amounts in his monthly report and pays, at the same time as his contribution to the Comité paritaire, the amounts for annual vacation and general holidays, that is a total of 10.36 %.

6.03.2. Payment of the indemnities: Each employee receives the indemnities for his annual vacation and his general holidays in two instalments.

6.03.3. The Comité paritaire pays the first instalment by cheque mailed to the last known address of the employee before 30 June. Such instalment applies to the indemnities due for the period extending from 1 July to 31 December of the preceding year.

6.03.4. The Comité paritaire pays the second instalment by cheque mailed to the last known address of the employee before 30 November. Such instalment applies to the indemnities due for the period extending from 1 January to 30 June of the current year.

6.03.5. Exception: However, on the death of an employee or in the event that an employee definitely quits his employment, the Comité paritaire may, at any time, claim the indemnities for the annual vacation and general holidays due to the employee.”.

2. This Decree comes into force on the day of its publication in the *Gazette officielle du Québec*.

3575

M.O., 2000-006

Order of the Minister of State for Health and Social Services and Minister of Health and Social Services making the Regulation to amend the Regulation respecting the List of medications covered by the basic prescription drug insurance plan, dated 6 April 2000

An Act respecting prescription drug insurance (R.S.Q., c. A-29.01; 1999, c. 37)

THE MINISTER OF STATE FOR HEALTH AND SOCIAL SERVICES AND MINISTER OF HEALTH AND SOCIAL SERVICES,

CONSIDERING section 60 of the Act respecting prescription drug insurance (R.S.Q., c. A-29.01; 1999, c. 37);

CONSIDERING Minister's Order 1999-014 dated 15 September 1999 of the Minister of State for Health and Social Services and Minister of Health and Social Services making the Regulation respecting the List of medications covered by the basic prescription drug insurance plan;

CONSIDERING that it is necessary to amend the List of medications attached to that regulation;

CONSIDERING that the Conseil consultatif de pharmacologie has been consulted on the draft regulation;

MAKES the Regulation to amend the Regulation respecting the List of medications covered by the basic prescription drug insurance plan, the text of which is attached hereto.

Québec, 6 April 2000

PAULINE MAROIS,
*Minister of State for Health and Social Services
and Minister of Health and Social Services*

Regulation to amend the Regulation respecting the List of medications covered by the basic prescription drug insurance plan*

An Act respecting prescription drug insurance (R.S.Q., c. A-29.01, s. 60; 1999, c. 37, s. 4)

1. The Regulation respecting the List of medications covered by the basic prescription drug insurance plan is amended, in the List of medications attached thereto, by inserting the following in Appendix IV entitled “Exceptional medications, with recognized indications for payment purposes”, after the medication “DOLASETRON MESYLATE” and the accompanying indications:

“DONEPEZIL HYDROCHLORIDE:

for treatment of persons suffering from Alzheimer's disease at the mild to moderate stage.

* The Regulation respecting the List of medications covered by the basic prescription drug insurance plan, made by Minister's Order 1999-014 dated 15 September 1999 (1999, *G.O.* 2, 3197) of the Minister of State for Health and Social Services and Minister of Health and Social Services, was last amended by Minister's Orders 2000-001 dated 3 February 2000 (2000, *G.O.* 2, 895) and 2000-005 dated 15 March 2000 (2000, *G.O.* 2, 1423) of that Minister. For previous amendments, refer to the *Tableau des modifications et Index sommaire*, Éditeur officiel du Québec, 2000, updated to 1 February 2000.

Upon the initial request (beginning of treatment or in the case of persons who have been taking donepezil for less than 6 months):

- the person's MMSE score must be between 10 and 26;
- and
- the physician must indicate the degree to which the person is affected (intact domain, mildly, moderately or severely affected) in the following five domains:
 - intellectual function, including memory;
 - mood;
 - behavior;
 - autonomy in activities of daily living (ADL) and in instrumental activities of daily living (IADL);
 - social interaction (including the ability to carry on a conversation).

The maximum initial duration of authorization is 6 months.

Upon subsequent requests (maintenance treatment and in the case of persons who have been taking donepezil for more than 6 months), the physician must provide evidence of a beneficial effect:

- diminution of the person's MMSE score by 2 points or less;
- and
- stabilization of or improvement in symptoms, in one or more of the following domains:
 - intellectual function, including memory;
 - mood;
 - behavior;
 - autonomy in activities of daily living (ADL) and in instrumental activities of daily living (IADL);
 - social interaction (including the ability to carry on a conversation).

The maximum duration of authorization is 6 months.”.

2. The List of medications, attached to the Regulation, is amended by inserting the following in the “Exceptional Medications” section, after the medication “DOLASETRON MESYLATE” and the accompanying information:

CODE	BRAND NAME	MANUFACTURER	PKG. SIZE	COST OF PKG. SIZE	UNIT PRICE
------	------------	--------------	-----------	-------------------	------------

DONEPEZIL HYDROCHLORIDE 

Tab. 5 mg

02232043	Aricept	Pfizer	30	132.30	4.4100
----------	---------	--------	----	--------	--------

Tab. 10 mg

02232044	Aricept	Pfizer	30	132.30	4.4100
----------	---------	--------	----	--------	--------

3. This Regulation comes into force on 19 April 2000.

3574